Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group

S. Kreissl, H. Müller, H. Goergen, J. Meissner, M. Topp, M. Sökler, J. Markova, J. Bernhard, R. Greil, B. von Tresckow, K. Behringer, JU. Rüffer, HH. Flechtner, M. Möstl, M. Fuchs, A. Engert, V. Diehl, P. Borchmann

. 2020 ; 38 (25) : 2839-2848. [pub] 20200623

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012214

PURPOSE: Many important details of health-related quality of life (HRQoL) after diagnosis and treatment of Hodgkin lymphoma (HL) are still unknown because large longitudinal studies of HRQoL are rare. Therefore, we analyzed a systematically assessed, comprehensive range of HRQoL domains in patients with HL of all stages from diagnosis up to 5 years of survivorship. PATIENTS AND METHODS: We included patients with HL age 18-60 years at diagnosis from the German Hodgkin Study Group trials HD13, HD14, and HD15. We analyzed HRQoL using all functional and symptom scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 including deviations from reference values. We estimated the effect of different disease, patient, and treatment characteristics using multiple regression and repeated measures analysis and computed correlations of HRQoL scores. RESULTS: We analyzed 4,215 patients with any HRQoL assessment within 5 years after treatment. Higher tumor burden at diagnosis was associated with impaired baseline scores in many HRQoL domains. During survivorship, cognitive, emotional, role, and social functioning and fatigue, dyspnea, sleep, and financial problems were severely and persistently affected. From year 2 on, mean deviations from reference values ranged between 12 and 29 points, with 10 points being a commonly used margin of clinical relevance. In all 3 trials, HRQoL domains 2 and 5 years after therapy were significantly influenced by baseline scores and age but not by randomized treatments. Fatigue was most closely correlated with other symptoms and scales. CONCLUSION: Our results show a high and persistent amount of different HRQoL deficits in survivors of HL that are largely independent of the applied chemotherapies. Our analysis underscores the high, unmet medical need of these rather young survivors of HL regarding the psychosocial adverse effects of the cancer experience.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012214
003      
CZ-PrNML
005      
20210507103121.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.03160 $2 doi
035    __
$a (PubMed)32574114
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kreissl, Stefanie $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
245    10
$a Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group / $c S. Kreissl, H. Müller, H. Goergen, J. Meissner, M. Topp, M. Sökler, J. Markova, J. Bernhard, R. Greil, B. von Tresckow, K. Behringer, JU. Rüffer, HH. Flechtner, M. Möstl, M. Fuchs, A. Engert, V. Diehl, P. Borchmann
520    9_
$a PURPOSE: Many important details of health-related quality of life (HRQoL) after diagnosis and treatment of Hodgkin lymphoma (HL) are still unknown because large longitudinal studies of HRQoL are rare. Therefore, we analyzed a systematically assessed, comprehensive range of HRQoL domains in patients with HL of all stages from diagnosis up to 5 years of survivorship. PATIENTS AND METHODS: We included patients with HL age 18-60 years at diagnosis from the German Hodgkin Study Group trials HD13, HD14, and HD15. We analyzed HRQoL using all functional and symptom scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 including deviations from reference values. We estimated the effect of different disease, patient, and treatment characteristics using multiple regression and repeated measures analysis and computed correlations of HRQoL scores. RESULTS: We analyzed 4,215 patients with any HRQoL assessment within 5 years after treatment. Higher tumor burden at diagnosis was associated with impaired baseline scores in many HRQoL domains. During survivorship, cognitive, emotional, role, and social functioning and fatigue, dyspnea, sleep, and financial problems were severely and persistently affected. From year 2 on, mean deviations from reference values ranged between 12 and 29 points, with 10 points being a commonly used margin of clinical relevance. In all 3 trials, HRQoL domains 2 and 5 years after therapy were significantly influenced by baseline scores and age but not by randomized treatments. Fatigue was most closely correlated with other symptoms and scales. CONCLUSION: Our results show a high and persistent amount of different HRQoL deficits in survivors of HL that are largely independent of the applied chemotherapies. Our analysis underscores the high, unmet medical need of these rather young survivors of HL regarding the psychosocial adverse effects of the cancer experience.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a přežívající onkologičtí pacienti $7 D000073116
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a Hodgkinova nemoc $x diagnóza $x mortalita $x patologie $x psychologie $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kvalita života $7 D011788
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Německo $x epidemiologie $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Müller, Horst $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Goergen, Helen $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Meissner, Julia $u University of Heidelberg, Heidelberg, Germany
700    1_
$a Topp, Max $u University Hospital of Würzburg, Würzburg
700    1_
$a Sökler, Martin $u Hematology Oncology, University Hospital Tübingen, Tübingen, Germany
700    1_
$a Markova, Jana $u Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Bernhard, Jürg $u Department of Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland $u Swiss Group for Clinical Cancer Research, Berne, Switzerland
700    1_
$a Greil, Richard $u Third Medical Department, Paracelsus Medical University, Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria
700    1_
$a von Tresckow, Bastian $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Behringer, Karolin $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Rüffer, Jens-Ulrich $u German Fatigue Society, Cologne, Germany
700    1_
$a Flechtner, Hans-Henning $u Department of Child and Adolescent Psychiatry and Psychotherapy, Otto von Guericke University, Magdeburg, Germany
700    1_
$a Möstl, Michaela $u Third Medical Department, Hanusch Krankenhaus, Vienna, Austria
700    1_
$a Fuchs, Michael $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Engert, Andreas $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Diehl, Volker $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
700    1_
$a Borchmann, Peter $u German Hodgkin Study Group, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 38, č. 25 (2020), s. 2839-2848
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32574114 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103120 $b ABA008
999    __
$a ok $b bmc $g 1650563 $s 1132593
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 25 $d 2839-2848 $e 20200623 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace